HIV/human T-cell lymphotropic virus coinfection revisited: Impact on AIDS progression

AIDS Reviews

Volumn 11, Issue 1, 2009, Pages 8-16

  Brites, Carlos ^a   Sampaio, Julio ^a   Oliveira, Adriano ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

Coinfection; HIV 1; HTLV 1; HTLV 2

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DISEASE ASSOCIATION; DISEASE COURSE; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS INFECTION; MIXED INFECTION; NONHUMAN; ORGANISMAL INTERACTION; REVIEW; SURVIVAL TIME; T LYMPHOCYTE; GEOGRAPHY; PATHOPHYSIOLOGY; PREVALENCE; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; GEOGRAPHY; HIV-1; HTLV-I INFECTIONS; HTLV-II INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2; HUMANS; PREVALENCE;

EID: 65549143352     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Poiesz B, Ruscetti F, Gazdar A, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T cell lymphoma. Proc Natl Acad Sci USA. 1980; 77:7415-9.
2. Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA. 1982;79:2031-5.
3. Hinuma Y, Nagata K, Misaka M, et al. Adult T cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA. 1981;78:6476-80.
4. Yoshida M, Seiki M, Yamaguchi K, Takatsuki K. Monoclonal integration human T-cell leukemia provirus in all primary tumors of adult T cell leukemia suggests causative role of human T-cell leukemia virus in disease. Proc Natl Acad Sci USA. 1984;81:2534-7.
5. Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-lymphotropic virus type-1 in patients with tropical spastic paraparesis. Lancet. 1985;2:407-10.
6. Osame M, Usuku K, Izumo S, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet. 1986;1:1031-2.
7. Kaplan J, Osame M, Kubota H, et al. The risk of development of HTLVI-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. J Acquir Immune Defic Syndr. 1990;3:1 096-101.
8. Mochizuki M, Watanabe T, Yamaguchi K, et al. HTLV-I uveitis: a distinct clinical entity caused by HTLV-I. Jpn J Cancer Res. 1992;83:236-9.
9. Yamaguchi K, Mochizuki M, Watanabe T, et al. Human T-lymphotropic virus type I uveitis. Leukemia. 1994;8(Suppl 1):S88-90.
10. LaGrenade L, Hanchard B, Fletcher V, et al. Infective dermatitis of Jamaican children: a marker for HTLV-I infection. Lancet. 1990;336: 1345-7.
11. Maloney E, Wiktor S, Palmer P, et al. A cohort study of health effects of human T-cell lymphotropic virus type I infection in Jamaican children. Pediatrics. 2003;112:e136-42.
12. Oliveira M, Brites C, Ferraz N, Magalhaes P, Almeida F, Bittencourt A. Infective dermatitis associated with the human T cell lymphotropic virus type I in Salvador, Bahia, Brazil. Clin Infect Dis. 2005;40: e90-6.
13. de The G, Bomford R. An HTLV-I vaccine: why, how, for whom? AIDS Res Hum Retroviruses. 1993;9:381-6.
14. Gallo R. The discovery of the first human retrovirus: HTLV-1 and HTLV2. Retrovirology. 2005;2:17.
15. Kalyanaraman V, Sarngadharan M, Robert-Guroff M, et al. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science. 1982;218:571.
16. Page J, Lai S, Chitwood D, et al. HTLV I/II seropositivity and death from AIDS among HIV-1 seropositive intravenous drug users. Lancet. 1990; 335:1439-41.
17. Safaeian M, Wilson L, Taylor E, et al. HTLV-II and bacterial infections among injection drug users. J Acquir Immune Defic Syndr. 2000; 24:483-7.
18. Orland J, Wang B, Wright D, et al. Increased mortality associated with HTLV-II infection in blood donors: a prospective cohort study. Retrovirology. 2004;1:4.
19. Roucoux D, Murphy EL. The epidemiology and disease outcomes of human T-lymphotropic virus type II. AIDS Rev. 2004;6:144-54.
20. UNAIDS. Report on the Global AIDS epidemic, 2008. (unaids.org Accessed 09/15/08).
21. Gallo R, Salahuddin S, Popovic M, et al. Human T-lymphotropic retrovirus, HTLV-III, isolated from AIDS patients and donors at risk of AIDS. Science. 1984;224:500-3.
22. Ratner L, Haseltine W, Patrarca R, et al. Complete nucleotide sequence of the AIDS virus. Nature. 1985;313:277-84.
23. Wain-Robson S, Sonigo P, Danos O, et al. Nucleotide sequence of the AIDS virus. Cell. 1985;40:9-17.
24. Wong-Staal F, Gallo R. Human T-Lymphotropic retroviruses. Nature. 1985;317:395-403.
25. Coskun, A, Sutton, R. Expression of glucose transporter 1 confers susceptibility to human T cell leukemia virus envelope-medicated fusion. J Virol. 2005;79:4150.
26. Manel N, Kim F, Kinet S, Taylor N, Sitbon M, Battini J. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell. 2003;115: 449-59.
27. Takenouchi N, Jones K, Lisinski I, et al. GLUT1 is not the primary binding receptor but is associated with cell-cell transmission of HTLV-1. J Virol. 2007;81:1506-10.
28. Ghez, D, Lepelletier, Y, Lambert, S, et al. Neuropilin-1 is involved in human T-cell lymphotropic virus type 1 entry. J Virol. 2006;80:6844.
29. Richardson J, Edwards A, Cruickshank J, Rudge P, Dalgleish A. In vivo cellular tropism of HTLV-1. J Virol. 1990;64:5682-7.
30. Nagai M, Brennan M, Sakai J, Mora C, Jacobson S. CD8(+) T-cells are an in vivo reservoir for HTLV-1. Blood. 2001;98:1858-61.
31. Ijichi S, Ramundo M, Takahashi H, Hall W. In vivo cellular tropism of HTLV-2. J Exp Med. 1992;176:293-6.
32. Lal R, Owen S, Rudolph D, Dawson C, Prince H. In vivo cellular tropism of HTLV-2 is not re stricted to CD8+ cells. Virology. 1995;210: 441-7.
33. Ho D, Neumann A, Perelson A, Chen W, Leonard J, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123-6.
34. Wei X, Ghosh S, Taylor M, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;373:117-22.
35. Etoh K, Yamaguchi K, Tokudome S, et al. Rapid quantification of HTLV-1 provirus load: detection of monoclonal proliferation of HTLV-1 infected cells among blood donors. Int J Cancer. 1999;81:859.
36. Igakura T, Stinchcombe J, Goon PK, et al. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science. 2003;299:1713-6.
37. Kakuda, K, Ikematsu, H, Chong W, et al. Molecular epidemiology of human T lymphotropic virus type 1 transmission in Okinawa, Japan. Am J Trop Med Hyg. 2002;66:404.
38. Franchini G, Fukumoto R, Fullen J. T-cell control by human T-cell leukemia/lymphoma virus type 1. Int J Hematol. 2003;78:280-96.
39. Azimi N, Brown K, Bamford R, Tagaya Y, Siebenlist U, Waldmann T. Human T cell lymphotropic virus type I Tax protein transactivates interleukin 15 gene transcription through an NF.B site. Proc Natl Acad Sci USA. 1998;95:2452-7.
40. Ballard D, Bohnlein E, Lowenthal J, Wano Y, Franza B, Greene W. HTLV-I tax induces cellular proteins that activate the kappa B element in the IL-2 receptor alpha gene. Science. 1988;241:1652-5.
41. Bangham C. Human T-lymphotropic virus type 1 (HTLV-1): persistence and immune control. Int J Hematol. 2003;78:297-303.
42. Mosley A, Asquith B, Bangham C. Cell-mediated immune response to human T-lymphotropic virus type I. Viral Immunol. 2005;18:293-305.
43. Wodarz D, Hall S, Usuku K, et al. Cytotoxic T-cell abundance and virus load in human immunodeficiency virus type 1 and human T-cell leukemia virus type 1. Proc Biol Sci. 2001;268:1215-21.
44. Jacobson S, Reuben J, Streilein R, et al. Induction of CD4+ human T lymphotropic virus type-1 specific cytotoxic T lymphocytes from patients with HAM/TSP. Recognition of an immunogenic region of the gp46 envelope glycoprotein of human T lymphotropic virus type-1. J Immunol. 1991;146:1155.
45. Vine A, Witkover A, Lloyd A, et al. Polygenic control of human T lymphotropic virus type I (HTLV-I) provirus load and the risk of HTLV-I-associated myelopathy/tropical spastic paraparesis. J Infect Dis. 2002;186: 932-9.
46. Cavrois M, Gessain A, Gout O, et al. Common human T cell leukemia virus type 1 (HTLV-1) integration sites in cerebrospinal fluid and blood lymphocytes of patients with HTLV-1-associated myelopathy/tropical spastic paraparesis indicate that HTLV-1 crosses the blood-brain barrier via clonal. J Infect Dis. 2000;182:1044-50.
47. Lee S, Morcos Y, Jang H, Stuart J, Levin M. HTLV-1 induced molecular mimicry in neurological disease. Curr Top Microbiol Immunol. 2005;296: 125-36.
48. Levin M, Lee S, Kalume F, et al. Autoimmunity due to molecular mimicry as a cause of neurological disease. Nat Med. 2002;8:455-7.
49. Porto A, Santos S, Muniz A, et al. Helminthic infection downregulates type 1 immune responses in human T cell lymphotropic virus type 1 (HTLV-1) carriers and is more prevalent in HTLV-1 carriers than in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. J Infect Dis. 2005;191:612-8.
50. Marinho J, Galvão-Castro B, Rodrigues L, Barreto M. Increased risk of tuberculosis with human T-lymphotropic virus-1 infection: a case-control study. J Acquir Immune Defic Syndr. 2005;40:625-8.
51. Suzuki M, Dezzutti C, Okayama A, et al. Modulation of T-cell responses to a recall antigen in human T-cell leukemia virus type 1-infected individuals. Clin Diagn Lab Immunol. 1999;6:713-7.
52. Ozel M, Pauli G, Gelderblom H. The organization o the envelope projections on the surface of HIV. Arch Virol. 1988;100:255-66.
53. Preston B, Poiesz B, Loeb L. Fidelity of HIV-1 reverse transcriptase. Science. 1988;242:1168-71.
54. Dragic, T, Litwin, V, Allaway, G, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381 (6584):667-73.
55. Moore J, Trkola A, Dragic T. Co-receptors for HIV-1 entry. Curr Opin Immunol. 1997;9(4):551-62.
56. Cullen B, Greene W. Regulatory pathways governing HIV-1 replication. Cell. 1989;56:423-6.
57. Pantaleo G, Demarest J, Schacker T, et al. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci USA. 1997;94:254.
58. Musey L, Hughes J, Schacker T, et al. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med. 1997;337:1267.
59. Giorgi J, Lyles R, Matud J, et al. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr. 2002;29:346.
60. Moir S, Malaspina A, Ogwaro K, et al. HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci USA. 2001;98:10362.
61. Stein D, Korvick J, Vermund S. CD4+ lymphocyte cell enumeration for prediction of clinical course of HIV disease: A review. J Infect Dis. 1992; 165:352.
62. Centlivre M, Sala M, Wain-Hobson S, Berkhout B. In HIV-1 pathogenesis the die is cast during primary infection. AIDS. 2007;21:1.
63. Hogan C, Hammer S. Host determinants in HIV infection and disease. Part 2: genetic factors and implications for antiretroviral therapeutics. Ann Intern Med. 2001;134:978.
64. Pereyra F, Addo M, Kaufmann D, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis. 2008;197:563.
65. Paxton W, Martin S, Tse D, et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med. 1996;2:412.
66. Edlich R, Arnette J, Williams F, et al. Global epidemic of human T-cell lymphotropic virus type-I (HTLV-I). J Emerg Med. 2000;18:10919.
67. Li H, Biggar R, Miley W, et al. Provirus load in breast milk and risk of mother-to-child transmission of human T lymphotropic virus type I. J Infect Dis. 2004;190:1275-8.
68. Iga M, Okayama A, Stuver S, et al. Genetic evidence of transmission of human T cell lymphotropic virus type 1 between spouses. J Infect Dis. 2002;185:691-5.
69. Hisada M, Maloney E, Sawada T, et al. Virus markers associated with vertical transmission of human T lymphotropic virus type 1 in Jamaica. Clin Infect Dis. 2002;34:1551-7.
70. Manns A, Wilks R, Murphy E, et al. A prospective study of transmission by transfusion of HTLV-I and risk factors associated with seroconversion. Int J Cancer. 1992;51:886-91.
71. Miller G, Lewis L, Colman S, et al. Clustering of human T lymphotropic virus type I seropositive in Montserrat, West Indies: evidence for an environmental factor in transmission of the virus. J Infect Dis 1994;170:44-50.
72. Gotuzzo E, Arango C, de Queiroz-Campos A, Isturiz R. Human T-cell lymphotropic virus-I in Latin America. Infect Dis Clin North Am. 2000; 14:211-39.
73. Galvão-Castro B, Loures L, Rodrigues L, et al. Geographic distribution of human-T lymphotropic virus type-I among blood donors: A Brazilian nationwide study. Transfusion. 1997;37:242.
74. Catalan-Soares B, Proietti F, Carneiro-Proietti A. Heterogeneous distribution of HTLV-1/II prevalence rates in blood donors from urban areas in Brazil. Vox Sang. 2004;87:105.
75. Rego F, Alcântara L, Moura Neto J, et al. HTLV type 1 molecular study in Brazilian villages with African characteristics giving support to the post-Columbian introduction hypothesis. AIDS Res Hum Retroviruses. 2008;24:673-7.
76. Shindo N, Alcântara L, Van Dooren S, et al. Human retroviruses (HIV and HTLV) in Brazilian Indians: seroepidemiological study and molecular epidemiology of HTLV type 2 isolates. AIDS Res Hum Retroviruses. 2002;18:71-7.
77. Brites C, Harrington W, Pedroso C, Netto E, Badaró R. Epidemiological characteristics of HTLV-I and II co-infection in Brazilian subjects infected by HIV-1. Braz J Infect Dis. 1997;1:43-8.
78. Moreira E, Ribeiro T, Swanson P, et al. W. Soroepidemiology of human T-cell lymphotropic virus type I/II in Northeastern Brazil. J Acquir Immune Defc Syndr Hum Retrovirol. 1993;6:959-63.
79. Dourado I, Andrade T, Carpenter C, Galvão-Castro B. Risk factors for human T-cell lymphotropic virus type I among injecting drug users in northeast Brazil: possibly greater efficiency of male to female transmission. Mem Inst Oswaldo Cruz. 1999;94:13-8.
80. Andrade T, Dourado I, Galvao-Castro B. Associations among HTLV-I, HTLV-II, and HIV in injecting drug users in Salvador, Brazil. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:186-7.
81. Beilke M, Theall K, O'Brien M, et al. Clinical outcomes and disease progression among patients coinfected with HIV and human T lymphotropic virus types 1 and 2. Clin Infect Dis. 2004;39:256-63.
82. Stuver S, Tachibana N, Okayama A, et al. Heterosexual transmission of human T cell leukemia/lymphoma virus type 1 among married couples in southwestern Japan: an initial report from the Miyazaki Cohort Study. J Infect Dis. 1993;167:57.
83. Kaplan J, Khabbaz R, Murphy E, et al. Male to female transmission of human T cell lymphotropic virus types I and II: association with viral load. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12:193.
84. Wignall F, Hyams K, Phillips I, et al. Sexual transmission of human T lymphotropic virus type 1 in Peruvian prostitutes. J Med Virol. 1992;38:44.
85. Murphy E, Figueroa J, Gibbs W, et al. Sexual transmission of human T lymphotropic virus type 1 (HTLV-1). Ann Intern Med. 1989;111:555.
86. Moriuchi H, Moriuchi M, Fauci A. Factors secreted by human T lymphotropic virus type I (HTLV-I)-infected cells can enhance or inhibit replication of HIV-1 in HTLV-I-uninfected cells: implications for in vivo coinfection with HTLV-I and HIV-1. J Exp Med. 1998;187:1689-97.
87. Moriuchi H, Moriuchi M. In vitro induction of HIV-1 replication in resting CD4(+) T cells derived from individuals with undetectable plasma viremia upon stimulation with human T-cell leukemia virus type I. Virology. 2000;278:514-9.
88. Leung K, Nabel G. HTLV-1 transactivator induces interleukin-2 receptor expression through an NF.B-like factor. Nature. 1988;333:776-8.
89. Lawson V, Lee J, Doultree J, Marshall J, McPhee D. Visualisation of phenotypycally mixed HIV and HTLV-I virus particles by electron microscopy. J Biomed Sci. 2000;7:71-4.
90. Beilke M, Greenspan D, Impey A, Thompson J, Didier P. Laboratory study of HIV-1 and HTLV-I/II coinfection. J Med Virol. 1994;44: 132-43.
91. Montefiori DC, Mitchell W. Persistent coinfection of T lymphocytes with HTLV-II and HIV and the role of syncytium formation in HIV-induced cytopathic effect. Virology. 1987;160:372-8.
92. Guenthner P, Hershow R, Lal R, Dezzutti C. Effects of human T-lymphotropic virus type II on human immunodeficiency virus type 1 phenotypic evolution. Arch Virol. 2001;146:1617-22.
93. Bovolenta C, Pilotti E, Mauri M, et al. Retroviral interference on STAT activation in individuals coinfected with human T cell leukemia virus type 2 and HIV-1. J Immunol. 2002;169:4443-9.
94. Bassani S, López M, Toro C, et al. Influence of human T cell lymphotropic virus type 2 coinfection on virologic and immunological parameters in HIV type 1-infected patients. Clin Infect Dis. 2007;44:105-10.
95. Casoli C, Pilotti E, Bertazzoni U. Molecular and cellular interactions of HIV-1/HTLV coinfection and impact on AIDS progression. AIDS Rev. 2007;9:140-9.
96. Bartholomew C, Saxinger W, Clark J, et al. Transmission of HTLV-I and HIV among homosexual men in Trinidad. JAMA. 1987;257:2604-8.
97. Schechter M, Harrison L, Halsey N, et al. Co-infection with human T-cell lymphotropic virus type I and HIV in Brazil: impact on markers of HIV disease progression. JAMA. 1994;271:353-7.
98. Schechter M, Moulton L, Harrison L. HIV viral load and CD4+ lymphocyte counts in subjects coinfected with HTLV-I and HIV-1. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15:308-11.
99. Harrison L, Schechter M. Coinfection with HTLV-I and HIV: increase in HTLV-I-related outcomes but not accelerated HIV disease progression? AIDS Patient Care STDS. 1998;12:619-23.
100. Brites C, Goyanna F, França L, et al. Co-infection by HTLV-I/II increases the risk of strongyloidiasis and may lead to a delayed introduction of antiretroviral therapy for HIV infected patients. 11th CROI. San Francisco, 2004.
101. Bessinger R, Beilke M, Kissinger P, Jarrott C, Tabak O. Retroviral coinfections at a New Orleans HIV outpatient clinic. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:67-71.
102. Okubo S, Yasunaga K. Significance of viral coinfections by HIV, HTLV-I, Epstein-Barr virus, and cytomegalovirus for immunological abnormalities in hemophiliacs. Cancer Detect Prev. 1990;14:343-6.
103. Chavance M, Neisson-Vernant C, Quist D, Monplaisir N, Armengaud B, Chout R. HIV/HTLV-I coinfection and clinical grade at diagnosis. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8:91-5.
104. Gotuzzo E, Escamilla J, Phillips I, et al. The impact of HTLV type I/II infection on the prognosis of sexually acquired cases of AIDS. Arch Intern Med. 1992;152:1372-3.
105. Casseb J, Hong M, Salomao S, et al. Co-infection with HIV and HTLV-I: Reciprocal activation with clinical and immunologic consequences. Clin Infect Dis. 1997;25:1259-60.
106. Brites C, Oliveira A, Netto E. Coinfection with HIV and Human T lymphotropic virus type 1: what is the real impact on HIV disease? Clin Infect Dis. 2005;40:329-31.
107. Sobesky M, Couppie P, Pradinaud R, et al. Co-infection with HIV and HTLV-I and survival in AIDS stage. French Guiana Study. Presse Med. 2000;29:413-6.
108. Brites C, Alencar R, Gusmao R, et al. Co-infection with HTLV-1 is associated with a shorter survival time for HIV-1 infected patients in Bahia, Brazil. AIDS. 2001;15:2053-5.
109. Etzel A, Shibata G, Caseiro M, Segurado A. HTLV-I and HTLV-II co-infections are predictors of shorter survival in a Brazilian HIV sero-prevalent cohort. XV International AIDS Conference; Bangkok Thailand 2004 [abstract MoPeC3382].
110. Brites C, Goyanna F, França L, et al. Co-infection by HTLV-I/II increases the risk of strongyloidiasis and may lead to a delayed introduction of antiretroviral therapy for HIV infected patients. 11th CROI San Francisco 2004 [abstract O-38].
111. Feitosa G, Bandeira A, Sampaio D, Badaró R, Brites C. High prevalence of giardiasis and strongyloidiasis among HIV-infected patients in Bahia, Brazil. Braz J Infect Dis. 2001;:339-44.
112. Brites C, Weyll M, Pedroso C, Badaró R. Severe and Norwegian scabies are strongly associated with retroviral (HIV-1/HTLV-I) infection in Bahia, Brazil. AIDS. 2002;16:1292-3.
113. Visconti A, Visconti L, Bellocco R, et al. HTLV-II/HIV-1 coinfection and risk for progression to AIDS among intravenous drug users. J Acquir Immune Defic Syndr. 1993;6:1228-37.
114. Giacomo M, Franco EG, Claudio C, et al. Human T-cell leukemia virus type II infection among high risk groups and its influence on HIV-1 disease progression. Eur J Epidemiol. 1995;11:527-33.
115. Hershow R, Galai N, Fukuda K, et al. An international collaborative study of the effects of coinfection with human T-lymphotropic virus type II on human immunodeficiency virus type 1 disease progression in injection drug users. J Infect Dis. 1996;174:309-17.
116. Bessinger R, Beilke M, Kissinger P, Jarrott C, Tabak O. Retroviral coinfections at a New Orleans HIV outpatient clinic. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:67-71.
117. Willy R, Salas C, Macalino G, Rich J. Long-term non-progression of HIV1 in a patient coinfected with HTLV-II. Diagn Microbiol Infect Dis. 1999; 35:269-70.
118. Turci M, Pilotti E, Ronzi P, et al. Coinfection with HIV-1 and human T-Cell lymphotropic virus type II in intravenous drug users is associated with delayed progression to AIDS. J Acquir Immune Defic Syndr. 2006;41:100-6.
119. Goedert J, Fung M, Felton S, Battjes R, Engels E. Cause-specific mortality associated with HIV and HTLV-II infections among injecting drug users in the USA. AIDS. 2001;15:1295-302.
120. Zehender G, Colasante C, Santambrogio S, et al. Increased risk of developing peripheral neuropathy in patients coinfected with HIV-1 and HTLV-2. J Acquir Immune Defic Syndr. 2002;31:440-7.